These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 29397568)
1. CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. Hou X; Han W; Gan Q; Liu Y; Fang W J Clin Lab Anal; 2018 Jun; 32(5):e22369. PubMed ID: 29397568 [TBL] [Abstract][Full Text] [Related]
2. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
3. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114 [TBL] [Abstract][Full Text] [Related]
4. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608 [TBL] [Abstract][Full Text] [Related]
5. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151 [TBL] [Abstract][Full Text] [Related]
6. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091 [TBL] [Abstract][Full Text] [Related]
7. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494 [TBL] [Abstract][Full Text] [Related]
8. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117 [TBL] [Abstract][Full Text] [Related]
9. Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents. Tan SSN; Fong AYY; Mejin M; Gerunsin J; Kong KL; Chin FYY; Tiong LL; Lim MSH; Asri S; Khiew NZ; Voon CY; Mohd Amin NH; Cham YL; Koh KT; Oon YY; Ong TK Pharmacogenomics; 2017 Aug; 18(13):1225-1239. PubMed ID: 28745576 [TBL] [Abstract][Full Text] [Related]
10. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention. Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794 [TBL] [Abstract][Full Text] [Related]
11. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648 [TBL] [Abstract][Full Text] [Related]
12. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. Park MW; Her SH; Kim CJ; SunCho J; Park GM; Kim TS; Choi YS; Park CS; Koh YS; Park HJ; Kim PJ; Chung WS; Seung KB; Kim HS; Shin JG; Chang K Genet Med; 2016 Aug; 18(8):833-41. PubMed ID: 26699760 [TBL] [Abstract][Full Text] [Related]
14. Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. Ou W; He Y; Li A; Liu B; Jin L Int Heart J; 2016 Sep; 57(5):586-92. PubMed ID: 27488401 [TBL] [Abstract][Full Text] [Related]
15. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. Joo HJ; Ahn SG; Park JH; Park JY; Hong SJ; Kim SY; Choi W; Gwon H; Lim YH; Kim W; Kang WC; Cho YH; Kim YH; Yoon J; Shin W; Hong MK; Garg S; Jang Y; Lim DS Sci Rep; 2018 Jan; 8(1):1229. PubMed ID: 29352151 [TBL] [Abstract][Full Text] [Related]
16. Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. Galeazzi R; Olivieri F; Spazzafumo L; Rose G; Montesanto A; Giovagnetti S; Cecchini S; Malatesta G; Di Pillo R; Antonicelli R Drugs Aging; 2018 Jul; 35(7):649-656. PubMed ID: 29936693 [TBL] [Abstract][Full Text] [Related]
17. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
18. Multiple genetic mutations increase the risk of thrombosis associated with clopidogrel after percutaneous coronary intervention. Jin H; Song J; Shen X; Liang Q; Sun G; Yu Y Pharmacogenomics; 2023 Mar; 24(4):227-237. PubMed ID: 36891827 [TBL] [Abstract][Full Text] [Related]
19. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746 [TBL] [Abstract][Full Text] [Related]
20. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]